Overview

A Study to Evaluate the Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens

Phase:

Phase 2

Details

Lead Sponsor:

Spruce Biosciences